Barclays
ALNA

Barclays’s Allena Pharmaceuticals ALNA Stock Holding History

Barclays’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,019
Closed -$13K – 5154
2021
Q1 		$13K Buy
+9,019
New +$15K ﹤0.01% 4416
2019
Q4 		– Sell
-8,224
Closed -$32K – 7011
2019
Q3 		$32K Sell
8,224
-2,016
-20% -$8.65K ﹤0.01% 6096
2019
Q2 		$41K Buy
10,240
+6,963
+212% +$38K ﹤0.01% 6182
2019
Q1 		$23K Buy
+3,277
New +$23.8K ﹤0.01% 6306
2018
Q4 		– Sell
-4,629
Closed -$49K – 7514
2018
Q3 		$49K Buy
4,629
+3,779
+445% +$41.5K ﹤0.01% 6094
2018
Q2 		$11K Sell
850
-272
-24% -$3.92K ﹤0.01% 6518
2018
Q1 		$13K Buy
1,122
+268
+31% +$2.24K ﹤0.01% 6586
2017
Q4 		$9K Buy
+854
New +$10.5K ﹤0.01% 6543

Other funds holding ALNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Barclays's ALNA Position: Q2 2021 in Review

Barclays sold out of Allena Pharmaceuticals (ALNA) in Q2 2021, closing a stake of 9,019 shares — an estimated $13K sold.

Barclays first reported a position in ALNA in Q4 2017 and held it in 8 quarters. The position peaked at $49K in Q3 2018. 29 funds tracked by Wall St. Rank hold ALNA as of Q2 2021.

  • Barclays reported no remaining Allena Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 9,019 Allena Pharmaceuticals shares in Q2 2021, an estimated $13K.
  • Barclays first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 8 quarters.
  • Barclays's Allena Pharmaceuticals position peaked at $49K in Q3 2018.
  • 29 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.